Day one biopharmaceuticals holding company llc
Biotechnology:-Biological-Products-(No-Diagnostic-Substances)
DAWN
Executive/
Director
Links
Price
- Last Close
-
$ 13.45
$ -0.35 -2.54 %
Dec 5, 2024
- 52-Week High/Low
- $17.46 - $9.68
- YTD
- -7.9%
- Trading Volume
- 28,605
- Market Cap Full
- $ 1.2B
- Shares Outstanding
-
87M
Nov 1, 2023
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Q1 | - | - | - | - | - | - | - | -41.1% | -37.9% | 13.2% |
Q2 | - | - | - | - | - | - | -3.1% | 80.4% | -10.7% | -2% |
Q3 | - | - | - | - | - | - | 4.2% | 11.9% | 2.8% | - |
Q4 | - | - | - | - | - | - | -29% | 7.4% | 21.6% | - |
J | F | M | A | M | J | J | A | S | O | N | D | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 3.1% | 11.2% | -1.3% | -4.1% | - | - | - | - | - | - | - | - |
2023 | 1.2% | -15.4% | -27.4% | -7.3% | 7.3% | -10.2% | 10.9% | 1.9% | -9% | -3.6% | -2.1% | 26.1% |
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 28% | -32% | -8% |
Earnings
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Q1 | - | -2.58 | -0.48 | -0.59 |
Q2 | - | -5.04 | -0.6 | -0.61 |
Q3 | - | -0.33 | -0.53 | -0.54 |
Q4 | - | 3.33 | -0.56 | - |
A | -7.3 | -4.6 | -2.2 | -1.74 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Outstanding Shares
(In Millions) +
Jan 16, 2024
2021 | 2022 | 2023 | |
---|---|---|---|
Mar | - | 62 | 73.6 |
Jun | - | 61.9 | 73.6 |
Sep | 61.9 | 73.5 | 87 |
Dec | 61.9 | 73.5 | 87 |
SEC Filings
Financial Ratios
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Asset Management | |||||
Inventory / Stock Turnover | - | - | - | - | - |
Fixed Asset Turnover | - | - | - | - | - |
Total Asset Turnover | - | - | - | - | - |
Leverage | |||||
Debt Ratio | - | - | - | - | - |
Debt – Equity Ratio | - | - | - | - | - |
Interest Coverage | 29.4 | 36.5 | -0.5 | 7.5 | - |
Equity multiplier | - | - | - | - | - |